Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.

Clinics and research in hepatology and gastroenterology - 1 Dec 2018

Zhou Ye, Wang Xue-Bin, Qiu Xue-Ping, Shuai Zhang, Wang Chen, Zheng Fang

Abstract excerpt

AIM: Lots of studies have explored cyclin-dependent kinase inhibitor 2A (CDKN2A) promoter methylation in hepatocellular carcinoma (HCC), but the established results were controversial. Hence, we conducted the meta-analysis to comprehensively investigate the association between CDKN2A promoter methylation and HCC risk. METHODS: A comprehensive search was implemented through searching PubMed, Web of Science and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Genetic Predisposition to Disease

Share to Liver Neoplasms

Source

Identifiers

PMID: 30143452
DOI: 10.1016/j.clinre.2017.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.PMID 30143452Read ↗

Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma.Semantic proximity Read ↗

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical applicationSemantic proximity Read ↗

A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylationSemantic proximity Read ↗

Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkersSemantic proximity Read ↗

Sex and Race-Related DNA Methylation Changes in Hepatocellular Carcinoma.Semantic proximity Read ↗

CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular CarcinomaSemantic proximity Read ↗

Systematic analysis identifies CDKN2A as a prognostic biomarker for hepatocellular carcinomaSemantic proximity Read ↗

Advances in Epigenetics of Hepatocellular CarcinomaSemantic proximity Read ↗

p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survivalSemantic proximity Read ↗

Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.Semantic proximity Read ↗

Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changesSemantic proximity Read ↗

Hepatocellular Carcinoma Displays Distinct DNA Methylation Signatures with Potential as Clinical PredictorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.